This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Vosoritide for achondroplasia

< Back

Vosoritide for achondroplasia



May 2020

Vosoritide is in clinical development for the treatment of achondroplasia. Achondroplasia represents the most common form of short-limb dwarfism, a condition where the bones in the arms and legs do not form properly and are shorter than normal. Patients with achondroplasia have a short stature, an enlarged head with a prominent forehead, bowed legs, ear problems, respiratory issues, compression of the spinal cord, as well as short fingers, toes, lower legs and upper arms. No pharmacologic therapies have been approved for achondroplasia in the EU.

In patients with achondroplasia, the gene FGFR3 is permanently ‘switched on’, and this prevents the normal growth of bones, ultimately leading to bones that are shorter than normal. Vosoritide works by attaching to a receptor called natriuretic peptide receptor type B (NPR-B) on the surface of cells, which is thought to ‘switch off’ the activity of FGFR3. This is expected to stimulate the normal growth of bones, thereby improving the symptoms of the disease. If licenced, vosoritide will offer a therapy option for patients with achondroplasia who currently have no effective treatment available.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts